ArticleValue in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research2019
Excess Costs and Economic Burden of Obesity-Related Cancers in the United States.
Article in Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Costs of obesity, obesity-related complications, and weight loss in the United States: A systematic literature review.Journal of managed care & specialty pharmacy · 2025Pooled it
- Costs of multimorbidity: a systematic review and meta-analyses.BMC medicine · 2022Pooled it
- The future costs of cancer attributable to excess body weight in Brazil, 2030-2040.BMC public health · 2022Pooled it
- Evaluating health system expenditure across the rural-urban spectrum in New Zealand: a study protocol.BMJ open · 2025Article
- Healthy microbiome-moving towards functional interpretation.GigaScience · 2025Article
- The Burden of Obesity in Saudi Arabia: A Real-World Cost-of-Illness Study.ClinicoEconomics and outcomes research : CEOR · 2025Article
- Obesity-Associated Colorectal Cancer.International journal of molecular sciences · 2024Review
- A Multilabel Text Classifier of Cancer Literature at the Publication Level: Methods Study of Medical Text Classification.JMIR medical informatics · 2023Article
- The Role of BMI in Allostatic Load and Risk of Cancer Death.American journal of preventive medicine · 2023Article
- Trends and drivers of pharmaceutical expenditures from systemic anti-cancer therapy.The European journal of health economics : HEPAC : health economics in prevention and care · 2023Article
- Article
- Article
- An ecological study of obesity-related cancer incidence trends in Australia from 1983 to 2017.The Lancet regional health. Western Pacific · 2022Article
- Economic outcomes of antiobesity medication use among adults in the United States: A retrospective cohort study.Journal of managed care & specialty pharmacy · 2022Article
- Weight-centric treatment of depression and chronic pain.Obesity pillars · 2022Review
- Supporting Management of Noncommunicable Diseases With Mobile Health (mHealth) Apps: Experimental Study.JMIR human factors · 2022Article
- The ambiguous role of obesity in oncology by promoting cancer but boosting antitumor immunotherapy.Journal of biomedical science · 2022Review
- Direct medical costs of obesity in the United States and the most populous states.Journal of managed care & specialty pharmacy · 2021Article
- Prevalence and predictors of obesity-related cancers among racial/ethnic groups with metabolic syndrome.PloS one · 2021Article
- Attrition Bias in an Observational Study of Very Low-Energy Diet: A Cohort Study.Obesity (Silver Spring, Md.) · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundObesity is a significant risk factor of several cancers that imposes a substantial economic burden on US healthcare that remains to be quantified. We estimated the excess costs and economic burden of obesity-related cancers in the United States.
methodsFrom the Medical Expenditure Panel Survey (2008-2015) data, we identified 19 405 cancer survivors and 175 498 non-cancer individuals. We estimated annual health expenditures using generalized linear regression with log link and gamma distribution by cancer types (stratified by 11 obesity-related cancers and other cancer types), controlling for sociodemographic and clinical characteristics. All cost estimates were adjusted to 2015 USD value.
resultsThe average annual total health expenditures were $21 503 (95% CI, $20 946-$22 061) for those with obesity-related cancer and $13 120 (95% CI, $12 920-$13 319) for those with other cancer types. There was a positive association between body mass index and health expenditures among cancer survivors: for each additional 5-unit increase in body mass index, the average predicted expenditures increase by $1503 among those with obesity-related cancer and by $722 among those with other cancers. With adjustments for sociodemographic and clinical characteristics, the mean incremental expenditures of treating obesity-related cancer were 2.1 times higher than those of other cancers ($4492 vs $2139) and more considerable among the non-elderly cancer population. Obesity-related cancers accounted for nearly 43.5% of total direct cancer care expenditures, estimated at $35.9 billion in 2015.
conclusionThe economic burden of obesity-related cancer in the United States is substantial. Our findings suggest a need for the inclusion of comprehensive obesity prevention and treatment in cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.